Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC lowered its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 47.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 151,217 shares of the company’s stock after selling 134,519 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Teva Pharmaceutical Industries were worth $4,719,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Public Sector Pension Investment Board boosted its holdings in shares of Teva Pharmaceutical Industries by 11.5% in the third quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after acquiring an additional 69,000 shares in the last quarter. Thrivent Financial for Lutherans bought a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $4,029,000. Menora Mivtachim Holdings LTD. boosted its holdings in shares of Teva Pharmaceutical Industries by 1.1% in the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after acquiring an additional 427,000 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 2.0% in the third quarter. Victory Capital Management Inc. now owns 2,360,762 shares of the company’s stock valued at $47,687,000 after acquiring an additional 45,395 shares in the last quarter. Finally, WealthTrust Asset Management LLC bought a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $856,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Trending Headlines about Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Teva reported new real-world survey data showing AUSTEDO and AUSTEDO XR improved quality-of-life measures for Huntington’s disease chorea patients and reduced caregiver strain, supporting the outlook for one of its key branded medicines. Article Title
• Positive Sentiment: Teva expanded its European biosimilars business with the launch of AHZANTIVE, strengthening its growth strategy and broadening its presence in ophthalmology. Article Title
• Neutral Sentiment: Industry coverage highlighted Teva as a generic-drug stock to watch as biosimilars, complex generics and specialty drugs become increasingly important growth drivers. Article Title

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. UBS Group increased their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Saturday. The Goldman Sachs Group lifted their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Truist Financial lifted their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Finally, Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.78.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, CAO Amir Weiss sold 10,679 shares of the firm’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total transaction of $384,444.00. Following the completion of the sale, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at $720,576. This trade represents a 34.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Richard Daniell sold 30,000 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the sale, the executive vice president directly owned 55,755 shares of the company’s stock, valued at approximately $1,973,727. This represents a 34.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 421,470 shares of company stock worth $14,570,945. 0.54% of the stock is owned by insiders.

Teva Pharmaceutical Industries Stock Up 0.1%

TEVA stock opened at $34.21 on Monday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.99 and a 12 month high of $37.35. The firm has a market cap of $39.34 billion, a PE ratio of 25.72, a P/E/G ratio of 3.49 and a beta of 0.84. The firm has a 50 day simple moving average of $32.82 and a 200 day simple moving average of $31.68. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The business had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.